Dermatology Deals & Contracts in Healthcare Sector Reviewed in New Topical Report Available at MarketPublishers.com
New research report “Dermatology Partnering Terms and Agreements” developed by CurrentPartnering has been recently published by Market Publishers Ltd. According to the study, the major portion of dermatology partnering deals in the biopharma industry are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors psychiatry technology.
London, UK (PRWEB) October 29, 2012
The major portion of dermatology partnering deals in the biopharma industry are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors psychiatry technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Knowing the flexibility of a would-be partner's negotiated deals terms provides key insight into the negotiation process in terms of what is likely to be achieved during the negotiation of terms. Whilst smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered.
New research report “Dermatology Partnering Terms and Agreements” developed by CurrentPartnering has been recently published by Market Publishers Ltd.
Title: Dermatology Partnering Terms and Agreements
Published: October, 2012
Price: US$ 2,695.00
The report is designed to provide an in-depth understanding and unprecedented access to dermatology partnering deals and agreements entered into by the top healthcare companies worldwide, besides explaining how and why these companies enter these deals.
- trends in dermatology dealmaking in the biopharma industry since 2007;
- analysis of dermatology deal structure;
- access to headline, upfront, milestone and royalty data;
- access to hundreds of dermatology deal contract documents;
- comprehensive access to over 1500 dermatology deal records;
- the leading dermatology deals by value since 2007;
- most active dermatology dealmakers since 2007.
The available deals and contracts are listed by: headline value; upfront payment value; royalty rate value; stage of development at signing; deal component type; technology type; and specific therapy indication.
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN DERMATOLOGY DEALMAKING
2.2. Dermatology partnering over the years
2.3. Bigpharma dermatology dealmaking activity
2.4. Bigpharma not active in dermatology
2.5. Dermatology partnering by deal type
2.6. Dermatology partnering by industry sector
2.7. Dermatology partnering by stage of development
2.8. Dermatology partnering by technology type
2.9. Dermatology partnering by dermatology indication
2.10. Average deal terms for dermatology
2.10.1 Dermatology headline values
2.10.2 Dermatology upfront payments
2.10.3 Dermatology milestone payments
2.10.4 Dermatology royalty rates
CHAPTER 3 – LEADING DERMATOLOGY DEALS
3.2. Top dermatology deals by value
3.3. Top dermatology deals involving bigpharma
CHAPTER 4 – BIGPHARMA DERMATOLOGY DEALS
4.2. How to use bigpharma partnering deals
4.3. Bigpharma dermatology partnering company profiles
Johnson & Johnson
Merck & Co
CHAPTER 5 – DERMATOLOGY PARTNERING CONTRACTS DIRECTORY
5.2. By deal type
5.3. By stage of development
5.4. By technology type
CHAPTER 6 – DERMATOLOGY DEALMAKING BY INDICATION
6.2. Deals by therapeutic indication
Diabetic foot ulcer
Eczema Hair disorders
CHAPTER 7 – PARTNERING RESOURCE CENTER
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 – Directory of dermatology deals by company A-Z 2007-2012
Appendix 2 – Directory of dermatology deals by deal type 2007-2012
Manufacturing - OEM
Appendix 3 - Directory of dermatology deals by stage of development 2007-2012
Appendix 4 – Directory of dermatology deals by technology type 2007
Appendix 5 – Deal type definitions
ABOUT WILDWOOD VENTURES
Recent titles from CurrentPartnering
Order Form – Reports
TABLE OF FIGURES
More new research reports by the publisher can be found at CurrentPartnering page.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb10068833.htmView Comments and Join the Discussion!